Nearly all of Latin America was excluded from the deal, sparking concern the world is missing a critical opportunity to stop ...
Gilead Sciences, Inc. GILD entered into an exclusive option and license agreement with Tubulis, a Germany-based biotech ...
For oral medications that prevent new HIV infection to be effective, the patient must take certain actions, including ...
A recent phase 3 trial found that twice-yearly injections of Lenacapavir reduce the risk of contracting HIV by 96%. | Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback